ERBB2 and breast cancer: Similarly, a significantly better five-year DFS has been reported in HR-positive HER2-low early breast cancer compared to HER2-zero (HR = 0.31; 95% CI: 0.13-0.75; p = 0.01), reinforcing the hypothesis that HER2-low tumors may exhibit less aggressive behavior in this subgroup [19].